TrialThe Lancet. Oncology2021

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.

Martin J van den Bent et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.